Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 53, Issue 5, Pages 2189-2191Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01091-08
Keywords
-
Categories
Funding
- NIAID NIH HHS [U01 AI069399, U01AI069512, UM1 AI106701, U01 AI069512, U01AI069399, UM1 AI068632, UM1 AI068616, U01 AI068632] Funding Source: Medline
Ask authors/readers for more resources
Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) mu g.h/ml, 11.2 (8.0 to 17.5) mu g/ml, and 4.6 (1.7 to 12.5) mu g/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available